Algeta and IFE to collaborate on manufacture and supply of Alpharadin

Published: 19-Jan-2010

Algeta, a Norwegian developer of cancer drugs, and the Institute for Energy Technology (IFE), the international research institute for energy and nuclear technology based in Oslo, have agreed to collaborate on the manufacture and supply of Alpharadin for future commercial use and clinical trials. Financial terms have not been disclosed.


Algeta, a Norwegian developer of cancer drugs, and the Institute for Energy Technology (IFE), the international research institute for energy and nuclear technology based in Oslo, have agreed to collaborate on the manufacture and supply of Alpharadin for future commercial use and clinical trials. Financial terms have not been disclosed.

Alpharadin is a targeted alpha-pharmaceutical under clinical evaluation to improve survival in patients with bone metastases from advanced prostate cancer.

The agreement is the first part of Algeta's manufacturing strategy to produce and supply Alpharadin to meet the needs of its ongoing ALSYMPCA Phase III study and planned clinical trials in other cancer indications. This expanded capacity will supply expected commercial demand around the world following its approval and worldwide launch in collaboration with Bayer Schering Pharma.

Andrew Kay, Algeta's ceo, said: IFE has been an excellent manufacturer and supply partner of Alpharadin for all our clinical trials to date. We are very pleased to be able to extend this agreement to secure the future clinical and commercial supply of Alpharadin. This product has the potential to be one of the world's leading oncology products."

Eva Dugstad, executive vice president at the IFE, added: "As a result of this collaboration, we expect to expand the activities at the IFE Isotope Laboratories with 10-20 new employees that will benefit the whole of the Norwegian cluster within nuclear medicine."

See more

You may also like

Dosage Forms

Bayer Aspirin introduces Aspirina to the US pain market

Read more
Bayer Aspirin has provided families with fast pain relief for generations and is continuing the tradition of health and pain relief by launching Aspirina, a product familiar to the US Hispanic community

Trending Articles

  1. Continuous innovation: redefining the future of pharmaceutical manufacturing In an industry in which reliability is paramount and change can be slow, GEA has consistently proven that innovation and stability go hand in hand. Almost two decades ago, GEA introduced the first ConsiGma® continuous manufacturing (CM) system to the pharmaceutical market — a pioneering move that helped to reshape how oral solid dosage (OSD) forms are developed and produced
  2. Abselion launches AAVX and AAV9 Total Capsid Quantification Kits Ready-to-use solution for Amperia benchtop platform supports rapid, reliable quantification across a range of serotypes
  3. diaago and Peak Analysis & Automation partner to bring practical automation solutions to research laboratories Using diaago's customer-first approach with PAA’s decades of expertise in laboratory robotics, the collaboration promises to deliver solutions to streamline workflows, boost throughput and reduce bottlenecks
  4. Suncombe and Kindeva collaborate to deliver low-carbon inhalers to the NHS The partnership will develop next-generation pressurised metered-dose inhalers with low Global Warming Potential propellants, helping the NHS move closer to its Net Zero target
  5. Douglas Pharmaceuticals sets new benchmark for capsule quality with CI Precision Partnership delivers compliance confidence, efficiency gains and reduced waste

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Dosage Forms

Bayer Aspirin introduces Aspirina to the US pain market

Bayer Aspirin has provided families with fast pain relief for generations and is continuing the tradition of health and pain relief by launching Aspirina, a product familiar to the US Hispanic community
Manufacturing

Shift log management solution enhances shop floor efficiency at Bayer

Bayer AG's drug substance finishing plant in Charlottenburg, Germany, has adopted eschbach's Shiftconnector platform to streamline shop floor communication, eliminate inefficiencies and enhance operational excellence with real-time visibility and integrated workflows
Research & Development

LIfT BioSciences licenses Bayer's Cambridge lab facilities to advance oncology research

LIfT will use Bayer's Co.Lab facilities to advance its immuno-modulatory alpha neutrophil platform for the mitigation of treatment resistance in solid tumours
Regulatory

Bayer's acoramidis recommended for approval by the EMA's CHMP for cardiomyopathy

The orally administered transthyretin (TTR) stabiliser is suitable for patients with transthyretin amyloid cardiomyopathy, demonstrating at least a 90% TTR stabilisation capacity and a reduction in cardiovascular-related hospitalisations
Distribution

PanTera signs agreement with Bayer for the supply of actinium-225

The company will provide 225Ac for clinical trial needs
Research & Development

Recursion adds new chemical entity targeting fibrotic diseases to late discovery pipeline

Potential first-in-class molecule with novel target inlicensed from collaboration with Bayer
Packaging

Bayer joins the Blister Pack Collective to reduce single-use plastics in tablet packs

PA Consulting (PA), the company bringing ingenuity to life, and PulPac, the Swedish R&D and IP company behind Dry Molded Fiber, are pleased to announce the Consumer Health division of Bayer has joined the Blister Pack Collective
Subscribe now